S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Stock Gains Skipping Biotech (GENZ, CELG, GILD, AMGN, BIIB, ALXN, MNKD, HGSI, VVUS, DNDN, BBH, XBI, QQQQ)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally.  It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful resolution at that, to get interest going in the sector in.  We have run a feature at BioHealthInvestor.com showing how many key biotech stocks are being left in the dust despite the improvement from tax extensions, QE2, the move to risk-assets, and general economic improvements.

Those issues covered are Celgene Corporation (NASDAQ: CELG), Gilead Sciences Inc. (NASDAQ: GILD), Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), MannKind Corp. (NASDAQ: MNKD), Human Genome Sciences Inc. (NASDAQ: HGSI), VIVUS Inc. (NASDAQ: VVUS), and Dendreon Corporation (NASDAQ: DNDN)… most of which were flops this last week while the NASDAQ and the broader stocks performed well.  We also compared the Biotech HOLDRs (NYSE: BBH) and SPDR S&P Biotech (NYSE: XBI) to the PowerShares QQQ (NASDAQ: QQQQ) to highlight some of the underperformance.

Read the full report at BioHealthInvestor.com

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
David Beren |

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
52% of Americans Are Building Wealth While Ignoring Their Greatest Risk
David Beren |

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

Continue Reading

Jon C. Ogg |

Best BioHealth Stocks of 2010, Outlook for 2011 (JAZZ, DNDN, HGSI, ARIA, AMRN, NBIX, THRX)

2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the…
Douglas A. McIntyre |

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:…
Douglas A. McIntyre |

Biotech Business Daily (BIIB, VRTX, ALNY, STEM)

Here are some of the top stories affecting key drug and biotech stocks this Friday.  We also have links through…
Douglas A. McIntyre |

Many Biotechs Barely On Life Support (BPAX, CEGE, EPIX, IDMI, LJPC, NRGN, NFLD, TPTX)

We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped…
Jon C. Ogg |

The Unusual Suspects for the Week Ahead (ABKFQ, AAPL, BHP, BX, DYN, BSX, DELL, ETFC, GENZ, HGSI, JKS, MELA, NBG, PBR, RAI, STX, ST, WMT, HD)

The list of Unusual Suspects for the week ahead is a rather different list.  Some are due with earnings, some…
Douglas A. McIntyre |

BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)

Today is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves…
Douglas A. McIntyre |

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association…
Douglas A. McIntyre |

Long Line of Biotech Secondary Stock Offerings (MNKD, IDIX, ISPH, ARIA, ONTY, NBY, SOMX, ARNA, OXGN)

It seems that there is another endless line of biotech and emerging pharmaceutical companies which have raised cash or have…
Douglas A. McIntyre |

Biotech Business Daily (RIGL, BIIB, ARRY, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618